Mizoribine Induced Hand-Foot Syndrome.
- Author:
Jin Woo HONG
1
;
Su Young JEON
;
Ki Yeol LEE
;
Chae Young LEE
;
Ki Ho KIM
;
Young Hun KIM
Author Information
1. Department of Dermatology, Dong-A University College of Medicine, Busan, Korea. mucca@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Hand-foot syndrome;
Mizoribine
- MeSH:
Arthritis, Rheumatoid;
Biological Therapy;
Edema;
Erythema;
Exanthema;
Graft Rejection;
Hair Removal;
Hand-Foot Syndrome;
Hyperuricemia;
Imidazoles;
Immunity, Cellular;
Incidence;
Leukopenia;
Lupus Nephritis;
Lymphocytes;
Prurigo;
Purines;
Ribonucleosides
- From:Korean Journal of Dermatology
2010;48(7):642-645
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hand-foot syndrome is also known as palmar-plantar erythrodysesthesia, and it is a side effect that mostly occurs with chemotherapy or biologic therapy. It is characterized by a painful erythema and edema, which may be followed by dry or moist desquamation of the palms and soles. Mizoribine (MZR) is an imidazole nucleoside that blocks purine biosynthesis. It was found to inhibit both humoral and cellular immunity by selectively inhibiting proliferation of lymphocytes. MZR has been used for preventing renal transplant rejection and treating rheumatoid arthritis, nephritic syndrome and lupus nephritis. The principal adverse reactions are leukopenia, abnormal hepatic function and hyperuricemia. The cutaneous side effects are skin rash, prurigo and epilation, with an incidence of about 1.32%, 0.77% and 0.55%, respectively. To the best of our knowledge, no case of hand-foot syndrome associated with MZR has ever been published. Herein, we report that MZR, which has been widely used, may induce drug-induced hand-foot syndrome.
